332 related articles for article (PubMed ID: 37509293)
1. Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma.
Guerra P; Martini A; Pontisso P; Angeli P
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509293
[TBL] [Abstract][Full Text] [Related]
2. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
3. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.
Sas Z; Cendrowicz E; Weinhäuser I; Rygiel TP
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409139
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Heterogeneous Tumour-Associated Macrophages in Hepatocellular Carcinoma.
Agirre-Lizaso A; Huici-Izagirre M; Urretabizkaia-Garmendia J; Rodrigues PM; Banales JM; Perugorria MJ
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894344
[TBL] [Abstract][Full Text] [Related]
6. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy.
Fasano R; Shadbad MA; Brunetti O; Argentiero A; Calabrese A; Nardulli P; Calbi R; Baradaran B; Silvestris N
Life (Basel); 2021 Dec; 11(12):. PubMed ID: 34947886
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.
Li A; Ji B; Yang Y; Ye B; Zhu Q; Hu X; Liu Y; Zhou P; Liu J; Gao R; Zhou Q; Kang B; Jiang Y
Front Immunol; 2023; 14():1164448. PubMed ID: 37383234
[TBL] [Abstract][Full Text] [Related]
9. MAPK10 Expression as a Prognostic Marker of the Immunosuppressive Tumor Microenvironment in Human Hepatocellular Carcinoma.
Li H; Li Y; Zhang Y; Tan B; Huang T; Xiong J; Tan X; Ermolaeva MA; Fu L
Front Oncol; 2021; 11():687371. PubMed ID: 34408980
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
11. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.
Zhao M; Huang H; He F; Fu X
Front Immunol; 2023; 14():1188277. PubMed ID: 37275909
[TBL] [Abstract][Full Text] [Related]
12. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
Sheng J; Zhang J; Wang L; Tano V; Tang J; Wang X; Wu J; Song J; Zhao Y; Rong J; Cheng F; Wang J; Shen Y; Wen L; He J; Zhang H; Li T; Zhang Q; Bai X; Lu Z; Liang T
Gut; 2022 Jun; 71(6):1176-1191. PubMed ID: 34253573
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
Li R; Zhao W; Liang R; Jin C; Xiong H
Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
[No Abstract] [Full Text] [Related]
14. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
[TBL] [Abstract][Full Text] [Related]
15. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract][Full Text] [Related]
16. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
18. Potential of Compounds Originating from the Nature to Act in Hepatocellular Carcinoma Therapy by Targeting the Tumor Immunosuppressive Microenvironment: A Review.
Li Y; Li H; He Q; Yang X
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615387
[TBL] [Abstract][Full Text] [Related]
19. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic immune cells and potential immune-related markers in hepatocellular carcinoma.
Mai J; Hua X; Bian ZH; Xia Y; Zhao ZB; Lu M
Transl Cancer Res; 2022 Jul; 11(7):2262-2274. PubMed ID: 35966304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
